ArticleBMC complementary medicine and therapies2025
Effect of nipa palm (Nypa fruticans Wurmb.) vinegar on the incretin hormones and intestinal glucose transporters in type 2 diabetes mellitus rat model.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-assisted optimization of ultrasound-ohmic processing of hawthorn vinegar: antidiabetic activity, phenolic profiling, and molecular docking insights.Frontiers in nutrition · 2026Article
- A Review of Medicinal Plants from the Anak Dalam Tribe of Jambi: An Evaluation of Their Potential for Diabetic Wound Healing Effects-Current Status and Future Perspectives.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nipa palm vinegar has been traditionally used to lower blood glucose levels by diabetic patients. This study aims to analyse the effect of aqueous extract (AE) of nipa palm vinegar on glycemic parameters and glucose transporter-incretin hormonal system in type 2 diabetic rat. The model was established using a combination of high-fat diet (p.o.) and low dose streptozotocin (i.p.). AE (250, 500, and 1000 mg/kg) was administered orally once daily for 28 days. Biochemical parameters related to type 2 diabetes including fasting glucose, serum insulin, lipid profiles, incretin hormone, liver, and pancreatic histology were evaluated. Relative expression of jejunal glucose transporters was also determined. Induction of diabetes caused significant (p = 0.026) weight loss, hyperlgycemia, hypoinsulinemia, dyslipidemia and reduced incretin hormones. Diabetes onset also disturbed HOMA-IR and HOMA-ß cell function indices, altered the morphological features of hepatocytes and pancreatic islet and overexpressed intestinal glucose transporters, SGLT1 and GLUT2. Repetitive oral administration of AE (1000 mg/kg) for 28 days ameliorated the biochemical abnormalities and improved HOMA-β cell function of diabetic rats. Histological studies revealed AE treatment preserved the integrity of pancreatic islet and protected hepatocytes from degeneration and atrophic effects of streptozotocin. Further analysis suggested the effect of AE in stimulating incretin hormones secretion via the action of DPP4 inhibitor and by modulating jejunal SGLT1 expression. In conclusion, the study suggested AE exerted its antidiabetic effect partially by stimulating insulin secretion via incretin hormone and intestinal glucose transporter pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.